Recent Updates
Recently added Catalysts
ARDX Positive Sentiment Score: 70/100

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Monday, July 21, 2025 2 min read
Key Takeaway: Ardelyx, Inc. has announced that it will hold a conference call on August 4, 2025, to discuss its financial results for the second quarter of 2025. The company aims to provide insights into its business performance during the call. Ardelyx is known for its innovative, first-in-class medicines, with two commercial products approved in the U.S. Additionally, the company has international agreements for its key product, tenapanor, enhancing its global outreach.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ardelyx is set to provide an update on financial results, indicating active company performance.
  • The company has two approved commercial products in the U.S., highlighting its ongoing success.
  • Ardelyx has global partnerships for product commercialization, enhancing its market presence.

Full Press Release Details

WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Monday, August 4, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2025.
To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:

Frequently Asked Questions

When is Ardelyx's next conference call scheduled?

The next conference call for Ardelyx is on August 4, 2025, at 4:30 p.m. ET.

How can I participate in the Ardelyx conference call?

To join the conference call, dial (877) 346-6112 for domestic calls or (848) 280-6350 internationally.

Where can I listen to the Ardelyx conference call webcast?

The live audio and archived webcast will be available on Ardelyx's Investors section of their website.

What are the commercial products offered by Ardelyx?

Ardelyx markets two products in the U.S.: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor).

Who is commercializing tenapanor in Japan?

In Japan, Kyowa Kirin is responsible for the commercialization of PHOZEVEL® (tenapanor).

Tags: ARDX Viatris Investor Conferences Healthcare Ardelyx tenapanor IBSRELA financial results hyperphosphatemia
Last updated: Jul 21, 2025